ST Pharm has completed the trademark registration for its core mRNA platform technologies, including 5’ capping and lipid nanoparticle (LNP) drug delivery technology.

The 5’ capping technology, which stabilizes mRNA molecules, has been registered under the trademark SMARTCAP® in nine countries: South Korea, the United States, Europe, the United Kingdom, Japan, Australia, India, Israel, and Russia.

The lipid nanoparticle (LNP) technology, which enables the safe delivery of mRNA within the body, has been registered under the trademark STLNP® in ten countries: South Korea, the United States, Europe, the United Kingdom, China, Japan, Canada, Australia, India, and Israel.

SMARTCAP® and STLNP® are actively utilized in the mRNA CDMO business.